肝硬化儿童肝移植前的一期止血:肝病严重程度、血管性血友病因子和血小板计数的关键作用
这项概念验证研究于2022年1月至2023年7月前瞻性纳入27例肝移植前1天的肝硬化患儿和15例年龄匹配对照,用流式细胞术和微流控实验评估血小板功能及血浆蛋白。发现患儿存在无激动剂时轻微血小板活化及高浓度激动剂下活化降低,微流控实验识别出两个亚组:肝病严重且血小板计数较高者一期止血保留,另一组血小板计数较低伴中度血小板血栓形成受损;高VWF水平可能在高剪切下代偿血小板活化降低。
要点
- 肝硬化患儿移植前存在无激动剂时轻微血小板活化及高浓度激动剂下活化降低。
- 微流控实验识别两个亚组:肝病严重且血小板计数较高者一期止血保留。
- 另一亚组血小板计数较低伴中度血小板血栓形成受损,高VWF可能代偿。
核心结论
- 移植前识别出两个血小板血栓形成存在差异的亚组,可能取决于肝病严重程度、血小板计数和VWF水平。
- 这些亚组之间血小板干预需求是否不同需进一步临床研究。
研究设计与样本
- 概念验证研究,于2022年1月至2023年7月前瞻性纳入肝移植前1天的肝硬化患儿,并设年龄匹配对照组。
- 采用流式细胞术和微流控实验评估血小板功能,检测血浆VWF、含血小板反应蛋白1型基序的解整合素和金属蛋白酶13及可溶性糖蛋白VI。
- 部分患者在移植后3个月复查。
- 共纳入27例肝硬化患儿(主要为胆汁淤积性肝病)和15例对照,患儿儿科终末期肝病评分为-10至44。
主要发现
- 流式细胞术显示无激动剂时存在轻微血小板活化,高浓度激动剂下活化降低。
- 微流控实验显示患者间血小板血栓形成存在差异,识别出2个不同亚组:1组肝病严重且血小板计数较高,一期止血保留;另1组血小板计数较低伴中度血小板血栓形成受损。
- 高VWF水平可能代偿高剪切下血小板活化降低。
局限性
- 原文为概念验证研究。
- 原文结论指出这些亚组之间血小板干预需求是否不同需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombocytopenia is common in pediatric patients with cirrhosis, but the extent and relevance of functional platelet defects remain unclear. OBJECTIVES: This proof-of-principle study aimed to characterize platelet properties in cirrhotic children before living-donor liver transplantation using state-of-the-art platelet-based assays, hypothesizing that primary hemostasis in this group is well preserved. METHODS: From January 2022 to July 2023, pediatric cirrhotic patients were prospectively enrolled 1 day before liver transplantation. An age-matched control group was included. Platelet functionality was assessed using flow cytometry and microfluidic assays, along with plasma proteins including von Willebrand factor (VWF), a disintegrin and metalloproteinase with a thrombospondin type 13, and soluble glycoprotein VI. A subset of patients was also re-evaluated 3 months after transplant. RESULTS: Twenty-seven pediatric cirrhotic patients, primarily with cholestatic liver disease, and 15 controls were enrolled. Patients had pediatric end-stage liver disease scores from -10 to 44. Flow cytometry revealed subtle platelet activation in the absence of agonists and reduced activation with high agonist concentrations. Microfluidic assays revealed variations in platelet thrombus formation among the patients, identifying 2 distinct subgroups: 1 with severe liver disease and higher platelet counts, showing preserved primary hemostasis, and another with lower platelet count and moderate platelet thrombus impairment. High VWF levels likely compensated for reduced platelet activation under high shear. CONCLUSION: Two subgroups with differences in platelet thrombus formation under flow were identified pretransplantation, likely depending on severity of liver disease, platelet count, and VWF levels. Whether the need for platelet intervention is different between these subgroups requires further clinical investigation.
引用
- Dievoet MV, Baaten CCFMJ, Nagy M, et al. Primary hemostasis in children with cirrhosis prior to liver transplantation: key roles of liver disease severity, von Willebrand factor, and platelet count. J Thromb Haemost. 2025. PMID: 40254274. doi:10.1016/j.jtha.2025.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。